Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. News
  7. Summary
    BIIB   US09062X1037

BIOGEN INC.

(BIIB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Biogen : Canaccord Genuity Adjusts Biogen PT to $390 From $423, Maintains Buy Rating

10/22/2021 | 12:49pm EST


© MT Newswires 2021
All news about BIOGEN INC.
02:03pBiogen Loses Appeals Court Bid to Revive Multiple Sclerosis Drug Patent
MT
11:12aUS Court of Appeals Affirms District Court Decision That Biogen's 2028 Tecfidera Patent..
MT
11/22Biogen's Alzheimer's Drug Reportedly Caused Brain Swelling in Over One-Third of Patient..
MT
11/22Study Shows Biogen's Alzheimer's Drug Reportedly Shows Brain Swelling in 35% of Patient..
MT
11/22BIOGEN : Statement on JAMA Neurology Publication about Amyloid-Related Imaging Abnormaliti..
PU
11/19RBC Cuts Price Target on Biogen to $277 From $295 Amid Alzheimer's Updates, Maintains S..
MT
11/19BIOGEN INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
11/18BMO Capital Initiates Coverage of Biogen With Outperform Rating, $315 Price Target
MT
11/18Biogen Inc. - Update on Regulatory Review of Aducanumab in the European Union
AQ
11/18Asian Stock Markets Wobble on Tech, Property Outlooks
MT
More news
Analyst Recommendations on BIOGEN INC.
More recommendations
Financials (USD)
Sales 2021 10 878 M - -
Net income 2021 1 604 M - -
Net Debt 2021 2 311 M - -
P/E ratio 2021 22,1x
Yield 2021 -
Capitalization 34 628 M 34 628 M -
EV / Sales 2021 3,40x
EV / Sales 2022 3,16x
Nbr of Employees 9 100
Free-Float 85,5%
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | BIIB | US09062X1037 | MarketScreener
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Last Close Price 235,74 $
Average target price 350,78 $
Spread / Average Target 48,8%
EPS Revisions
Managers and Directors
Michel Vounatsos Chief Executive Officer & Director
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Chairman
Alfred W. Sandrock Head-Research & Development
Mark Hernon Chief Information Officer & Senior Vice President
Sector and Competitors